Inactive Instrument

DUCAT VENTURES Stock London S.E.

Equities

Biotechnology & Medical Research

End-of-day quote London S.E.
- GBX - Intraday chart for DUCAT VENTURES

Financials

Sales 2022 457K 583K 794K Sales 2023 644K 822K 1.12M Capitalization 24.39M 31.12M 42.36M
Net income 2022 2M 2.55M 3.47M Net income 2023 -2M -2.55M -3.47M EV / Sales 2022 24.1 x
Net cash position 2022 1.05M 1.34M 1.83M Net cash position 2023 635K 810K 1.1M EV / Sales 2023 36.9 x
P/E ratio 2022
4.77 x
P/E ratio 2023
-11.8 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.46%
More Fundamentals * Assessed data
Managers TitleAgeSince
Founder 64 06-06-18
Director of Finance/CFO 61 11-30
Director/Board Member - 14-11-17
Members of the board TitleAgeSince
Chairman 72 17-12-31
Director/Board Member 66 18-09-09
Founder 64 06-06-18
More insiders
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.
Calendar
More about the company